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Henoch-Schönlein purpura is the most common child-
hood vasculitis, but may also affect adults. This article 
reviews the literature since 2011 on advances in diag-
nosis, clinical disease manifestations, pathophysiology 
and treatment of Henoch-Schönlein purpura. The clini-
cal manifestations are thought to arise from IgA de-
positions in blood vessel walls in the affected organs, 
mostly skin, gastrointestinal tract, joints and kidneys. 
Corticosteroids may be effective in rapid resolution of 
renal manifestations and treating joint and abdomi-
nal pain, but they are not proven effective for treating 
organ manifestations and complications, such as glo-
merulonephritis, bowel infarction or intussusception. 
Mycophenolate mofetil or cyclosporine A may be better 
treatment choices in case of renal involvement. Other 
immunosuppressive and immunomodulating drugs, 
such as rituximab and dapsone, are promising, but 
larger studies are needed to confirm these findings. 
Cancer screening should be considered in older males 
diagnosed with Henoch-Schönlein purpura. 
Key words: Henoch-Schönlein purpura; vasculitis; immunoglo-
bulin A; corticosteroids.
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Henoch-Schönlein purpura (HSP) is the most com-mon childhood vasculitis, affecting 10–20 children 
per 100,000 per year. More than 90% of patients are 
under 10 years of age, with a mean age of 6 years (1, 
2). HSP is a leukocytoclastic vasculitis involving small 
vessels (3). Its clinical presentation includes cutaneous 
palpable purpura, joint pain, renal involvement, colicky 
abdominal pain and gastrointestinal bleeding. Most cases 
of HSP occur in autumn and winter. Proposed triggers 
include upper respiratory tract infections, medications, 
vaccinations, and malignancies (4, 5). The pathophysio-
logy behind HSP is not yet completely understood. HSP 
is generally self-limiting and harmless, but concomitant 
nephritis may cause severe complications. The proportion 
of patients having renal involvement varies between 20% 
and 80% in the literature (6). The estimated incidence 
of nephrotic or nephritic syndrome is ~7% of all HSP 
cases, and 1% of patients develop end-stage renal failure 
(7, 8). HSP nephritis (HSPN) usually occurs within 1–2 
months after the onset of HSP. 
The diagnosis of HSP is criteria-based. The European 
League Against Rheumatism (EULAR), the Paediatric 
Rheumatology International Trials Organization (PRIN-
TO) and the Paediatric Rheumatology European Society 
(PRES) published a revised set of criteria in 2010, with 
high sensitivity and specificity (9). 
The severity and organ involvement of the disease 
dictates the treatment. In general, treatment for HSP 
without renal involvement is symptomatic. HSPN is 
commonly treated with corticosteroids or other immu-
nosuppressive and modulating drugs. Existing studies 
are inconclusive regarding drug of choice. 
METHODS
A systematic search of the literature was performed in 
PubMed and Embase databases. The MeSH term in the 
PubMed database was “Henoch Schönlein purpura”, 
limited to the title, for articles published between 2011 
and 2016. This search yielded 508 articles. In the Embase 
database, the keywords were “henoch”, “henoch schön-
lein purpura”, “purpura” and “schönlein”. The same 
limitations applied. This search yielded 1,503 articles. 
The number of articles chosen for further reading was 
300. The references in the articles selected for this review 
were investigated further. 
DIAGNOSIS
HSP diagnosis is based on clinical criteria. The revised 
criteria developed by EULAR/PRINTO/PRES were 
published in 2010, and are the gold standard for the 
diagnosis of HSP (Table I). The sensitivity is 100% and 
specificity 87%, when applied to children (9). One study 
reviewed these criteria to assess applicability to adults, 
and found a diagnostic sensitivity of 99.2% and specifi-
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Table I. Diagnostic criteria for Henoch-Schönlein purpura (HSP), 
as developed by EULAR/PRINTO/PRES
Criterion Description
Mandatory criterion Purpura or petechiae with lower limb 
predominance
Minimum 1 out of 4 criteria 1. Diffuse abdominal pain with acute onset
2. Histopathology showing leukocytoclastic 
vasculitis or proliferative glomerulonephritis, with 
predominant immunoglobulin A (IgA) deposits
3. Arthritis or arthralgia of acute onset
4. Renal involvement in the form of proteinuria or 
haematuria
EULAR/PRINTO/PRES: the European League Against Rheumatism, the Paediatric 
Rheumatology International Trials Organization and the Paediatric Rheumatology 
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city of 86%, supporting its use for all patients with HSP 
(10). There are currently no specific biomarkers useful 
for diagnosis of HSP. Some biomarkers can show acti-
vity and prognosis of the disease, but none have proven 
clinically useful (11–13). 
Skin biopsies are the gold standard for diagnosing any 
cutaneous vasculitis. IgA-predominant vascular deposits 
are characteristic for HSP, but not sufficient for the di-
agnosis of HSP, as these deposits can be found in other 
vasculitic syndromes, erythema nodosum and venous 
stasis-related conditions (14). 
HISTOPATHOLOGY
The histological features of HSP involving the skin 
are those of a leukocytoclastic vasculitis primarily af-
fecting the small superficial vessels. The vessel walls 
are infiltrated by neutrophil granulocytes, which partly 
degenerate and form nuclear dust (leukocytoclasia), 
located amongst extravasated erythrocytes (purpura) in 
the surrounding dermis. The vessel walls are thickened 
and might be necrotic due to exudation of neutrophils 
and variable amounts of fibrin. On direct immunofluo-
rescence IgA and, eventually, complement C3 can be 
seen deposited in the vessel walls (Fig. 1). The process 
is dynamic and not all of these features might be seen 
in a single biopsy. Positive histology is one of the non-
mandatory criteria in the diagnostic criteria developed 
by EULAR/PRINTO/PRES (9). Several authors argue 
that skin biopsies are not indicated unless the diagnostic 
criteria based on clinical presentation are not met, or 
if the presentation is atypical or incomplete (15–17). 
An abstract included in the annual American College 
of Rheumatology/Association of Rheumatology Health 
Professionals (ACR/ARHP) meeting in 2016, describes 
leukocytoclastic vasculitis in 205 of 216 (92%) adult 
patients with HSP (18). Direct immunofluorescence 
revealed IgA deposition in dermal blood vessels in 
174/216 (81%) patients. One study analysed patients 
diagnosed with HSP and concomitant histological 
diagnosis of cutaneous leukocytoclastic vasculitis. 
They found IgA positivity associated with HSP with a 
sensitivity of 81% and a specificity of 83% (19).
CLINICAL MANIFESTATIONS
The classic tetrad of HSP includes palpable purpura, joint 
pain, gastrointestinal complaints, and renal involvement 
(Fig. 2). These clinical manifestations may develop over 
the course of days to weeks. The order of presentation 
may vary. The initial presentation is usually with purpura 
and joint pain (20). In a review of 150 children with HSP, 
all patients had palpable purpura (21). Seventy-four 
percent of patients had joint involvement. Renal and 
gastrointestinal involvement was seen in 54% and 51% 
of patients, respectively. A survey from 2016 analysed 
clinical symptoms in 260 adults with HSP (18). At di-
agnosis, 100% of patients presented with purpura. Joint 
involvement, glomerulonephritis and gastrointestinal in-
volvement were found in 62%, 70% and 53% of patients, 
respectively. One study compared symptoms in 75 adults 
vs. 208 children with HSP (22). Children had joint invol-
vement and abdominal pain more often than adults. There 
were more adult cases with lower extremity oedema and 
hypertension. Less common clinical manifestations of 
HSP include cerebral vasculitis, testicular haemorrhage 
and interstitial pulmonary haemorrhage (23). 
Skin manifestations
The rash often begins with petechiae and pal-
pable purpura. Occasionally, erythematous 
macular or urticarial wheals may also appear. 
The lesions may merge and evolve into ec-
chymoses, petechiae and palpable purpura, 
and could also turn into bullous or necrotic 
lesions (8, 20). Gravity-dependent areas and 
pressure points may favour the localization 
of rashes. The rash is especially common 
on the lower extremities and buttocks. The 
reason for this phenomenon is unclear, but 
some researchers have suggested that gravity 
causes immune complexes to deposit and 
incite inflammation in dependent areas (24). 
Up to one-third of patients experience trunk 
and upper extremity involvement (25). When 
the haemorrhagic skin lesions disappear, 
hemosiderin deposits will discolour the skin 
for weeks (26). 
Fig. 1. (A) Punch biopsy from skin showing neutrophils accentuated around and in 
superficial vessel walls. There are extravagated erythrocytes, leukocytoclasis and focal 
exudation of fibrin (haematoxylin-eosin stain x 150). (B) Positive IgA immunofluorescence 
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Joint manifestations
Fifteen percent of patients with HSP present arthritis as 
the initial symptom (21). Temporary, non-destructive 
poly arthralgias involving the knees and ankles are 
usually seen. Hands and feet may also be affected. The 
affected joints are painful, swollen and have reduced 
function (27). Arthralgia or arthritis involving only a 
few joints occurs in approximately 75% of children 
with HSP (23). 
Gastrointestinal involvement
In 10–40% of patients, gastrointestinal manifestations 
may precede the onset of skin purpura (11). The main 
explanation of these symptoms is immune complex 
deposition in the intestinal vessel walls. A prospective 
trial performed by Jauhola et al. (27) included 221 pa-
tients with HSP less than 16 years of age. Abdominal 
pain was found in 57% of these patients. Melaena and 
haematemesis were present in 18 and 2 of these patients, 
respectively. The article emphasized measurement of 
serum albumin levels in all patients with HSP, as hypo-
albuminaemia in the absence of proteinuria can indicate 
intestinal involvement and protein loss, also in patients 
without abdominal symptoms. A recent study on children 
showed that faecal calprotectin might also be a reliable 
marker for gastrointestinal involvement in HSP (28). In 
severe cases, gastrointestinal symptoms may mimic an 
acute surgical abdomen. Complications of abdominal 
involvement include perforations, intussusception and 
bowel infarctions. This can lead to death if surgical 
intervention is not initiated in time (29). 
Renal involvement (Henoch-Schönlein purpura nephritis)
In 20–55% of children with HSP, renal symptoms usually 
follow the onset of rash within 1–3 months (23). HSPN 
develops when the renal parenchyma is affected and 
HSPN is the leading cause of morbidity from this disease 
(30). Manifestations range from microscopic haematuria 
and mild proteinuria to nephrotic and nephritic syndrome 
and renal failure. Hypertension may develop at the onset 
or during recovery of HSP. The most common finding 
is isolated microscopic haematuria that usually develops 
within 4 weeks after onset of the disease. Most HSPN 
cases are mild, and the chances of recovery are good 
(8). Children with no renal symptoms during the first 6 
months after the onset of HSP are not likely to develop 
long-term renal damage (31). 
Central nervous system involvement
Although rare, HSP can have neurological manifesta-
tions. Clinical presentation appears from 2–4 weeks into 
the course of HSP (32). Most frequent symptoms are 
headaches, seizures and more non-specific changes in the 
central nervous system (CNS), which entail emotional 
instability, irritability, dizziness and behavioural changes. 
Other rare complications include ataxia, intracranial 
haemorrhage, mononeuropathy, and acute motor sensory 
axonal neuropathy.
Fig. 2. (A and B) Classical skin lesions of Henoch-Schönlein purpura, with palpable purpura on the extremities. (C) Arthritis and purpura on the 
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AETIOLOGY AND PATHOGENESIS
Upper respiratory tract infections precede a majority of 
HSP cases and multiple case studies propose a correlation 
between practically all respiratory pathogens and HSP. 
Streptococcus strains and Parainfluenza virus are the 
most commonly associated pathogens, and in children 
Human Parvovirus B19 is a frequent viral trigger (23, 
33, 34). The interaction between leukocytes and vascular 
endothelial cells contributes to the pathogenesis of HSP. 
Endothelial damage, perivascular leukocytic infiltrates, 
chemokines and cytokines are important factors in this 
process (35, 36). Vascular deposition of IgA1-containing 
immune complexes plays a pathogenic role (37). Com-
plement activation, cellular damaging and IgA deposi-
tion suggest that HSP is an IgA-mediated dysregulated 
immune response to an antigen (4). Through binding and 
activation of complement factors, IgA cross-reacts with 
endothelial cells and damages the cells. Advances in tech-
nology have allowed updated data on the function of the 
human immune system and what happens when it fails. 
In HSP, the dysregulated immune response may result 
in inflammation and vasculitis without a granulomatous 
reaction (26). Several antibodies, cytokines, chemokines, 
receptors, and transmembrane proteins have been found 
to be involved. Amongst these are cytokines, such as 
tumour necrosis factor alpha (TNF-alpha), interleukin 
(IL)-6, and IL-8 (38). Studies showed that Toll-like re-
ceptors TLR-2 and TLR-4 were upregulated in children 
with HSP. These proteins are mainly expressed, regulated 
and produced by cells of the immune system, including 
macrophages and lymphocytes. They may also arise from 
non-immune cells, such as epidermal cells, fibroblasts, 
kidney podocytes and mesangial cells (39, 40). One study 
stated that plasma levels of IgA anti-beta2-glycoprotein 
I antibodies are increased in childhood HSP (41). They 
are thought to have a strong association with heavy 
proteinuria and joint manifestations.
GENETICS
Genetic predisposition may contribute to the develop-
ment of HSP. An Israeli study demonstrated that 10% 
of patients with HSP were homozygous for mutations 
of the gene encoding MEFV (the gene defective in fa-
milial Mediterranean fever), and additionally 17% had 
heterozygous defects (42). In comparison, in a randomly 
selected cohort in the general Israeli population, only 
1–2% carried 2 mutant alleles. MEFV encodes the protein 
pyrin/marenostrin, which regulates caspase-1-activation 
and IL-1B production. Human leukocyte antigen hap-
lotypes may also play a role in susceptibility to HSP. A 
study on children with HSP showed an increased risk 
for the development of HSP in children carrying human 
leukocyte antigen A2, A11 and B35 antigens, and a 
reduced risk in the carriers of HLA A1, B49 and B50 
antigens (43).
TREATMENT
The treatment strategies for HSP remain controversial. 
The general agreement is to base therapy on the pre-
sence or absence of renal involvement. Without renal 
involvement, the treatment is purely symptomatic. Pain 
medication, rehydration therapy and surgery for intus-
susception are examples of this. In case of skin necrosis 
with ulceration, wound therapy may also be necessary. 
Compression therapy may be used when oedema of the 
lower legs occurs. There is still no consensus on treat-
ment of HSP nephritis and other severe complications.
Corticosteroids
There is disagreement between researchers and clinici-
ans whether to use corticosteroids. Over the last 6 years 
there have been some studies that can help clarify the 
applicability of corticosteroids. In 2013, Dudley et al. 
(44) conducted a double-blinded, randomized, placebo-
controlled trial of corticosteroids in 352 children with 
recent-onset HSP and no or minor renal involvement. 
Prednisolone was administered for 2 weeks, and the 
conclusion was, that treatment with corticosteroids 
demonstrated no benefit over placebo in reducing the 
risk of proteinuria 12 months after the onset of HSP. In 
addition, the trial did not determine how patients with 
more severe renal involvement during the course of the 
disease should be treated. Earlier studies, performed in 
2004 and 2006, including an 8-year follow-up, showed 
the same results, with no long-term benefit (45, 46). Re-
nal manifestations, such as haematuria and proteinuria, 
were not prevented after 28 days of corticosteroid tre-
atment, but were resolved faster compared with patients 
receiving placebo. At 6-month follow-up, 61% of pa-
tients had resolved renal manifestations compared with 
34% of placebo patients. This study showed the greatest 
efficacy in patients over 6 years of age presenting with 
mild renal manifestations at inclusion, and suggests the 
potential use of corticosteroids in mild cases in order to 
alter the course of renal involvement. The studies also 
found statistically significant results regarding treatment 
of extra-renal symptoms. Abdominal and joint pain were 
reported less frequently in patients receiving corticos-
teroid treatment vs. placebo. There was no difference 
between the groups with regard to skin manifestations. 
An updated Cochrane review from 2015 aimed 
to clarify the different treatment options for kidney 
involvement in patients with HSP, compared with 
placebo or other treatments (47). Five randomized 
controlled trials formed the basis for this review, and 
none of the studies presented evidence for the bene-
fit of corticosteroid treatment for renal involvement. 
A randomized controlled trial compared methylpredni-
solone and cyclosporine A as treatments for HSPN (45). 
Twenty-four children with nephrotic-range proteinuria 
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Eleven patients were treated with cyclosporine A, and all 
achieved resolution of proteinuria within 3 months. Of 
the 13 patients receiving methylprednisolone, 6 did not 
achieve resolution of proteinuria, and were treated with 
cyclosporine A as an alternative. Five of these patients 
responded to cyclosporine A. Biopsy outcomes after 
2 years were the same in the 2 treatment groups, but 
cyclosporine A showed faster regression of proteinuria 
and a higher frequency of response. 
Other immunosuppressive and immunomodulatory 
treatment
In one study, 12 children with steroid-resistant nephrotic-
range proteinuria received mycophenolate mofetil and 
all responded to the treatment with no relapses occurring 
(48). One systematic review of 10 RCTs involving 426 
patients aimed to assess the safety and efficacy of myco-
phenolate mofetil for HSPN vs. other immunosuppres-
sive therapies (49). The conclusion was that the efficacy 
of mycophenolate mofetil was better than cyclophospha-
mide after 12 months. Cyclophosphamide and prednisone 
caused more side-effects than mycophenolate mofetil. 
Dapsone is a drug known for its anti-inflammatory 
and immunomodulatory effects. It has been prescribed 
in a few individual cases. One patient presented chronic 
skin lesions of the legs, which disappeared within 24 h 
after initiating dapsone, and the patient remained asymp-
tomatic with a lower dose as maintenance therapy (50). 
In 3 other cases, dapsone was initiated as treatment for 
chronic, recurrent, persisting purpuric skin lesions. The 
outcome was complete healing in all cases (51). 
Rituximab is an anti-CD20 antibody, functioning as 
a B-cell inhibitor. The efficacy of this drug on HSP has 
been observed in several case studies over recent years. 
One case report described a patient with severe skin 
lesions and moderate kidney involvement, who after 2 
doses of rituximab showed complete remission (52). An-
other case study presented a patient with relapsing HSP, 
who was unresponsive to corticosteroid treatment and 
only mildly responsive to cyclophosphamide, who after 
5 courses of rituximab experienced complete remission 
of HSP (53). A patient with end-stage renal disease and 
corticosteroid-dependent HSP likewise had complete 
remission after 2 infusions of rituximab (54). 
A Cochrane Review regarding treatment of kidney 
disease in HSP assessed 2 studies in which the ef-
ficacy of cyclophosphamide was evaluated (47). One 
of the studies included 56 children with significant 
HSP-associated kidney disease who received either 
cyclophosphamide or supportive treatment (55). There 
was no significant difference in the risk of persistent 
kidney disease of any severity during follow-up between 
the 2 treatment groups. The other study compared cy-
clophosphamide plus corticosteroids vs. corticosteroid 
monotherapy in 54 adults with severe HSP. Adding 
cyclophosphamide provided no benefit compared with 
corticosteroids alone.
Miscellaneous
Anticoagulants, such as warfarin, dipyridamole and 
acetylsalicylic acid (ASA), have been used alongside 
immunosuppressive agents, supported by the possible 
role of fibrin deposition in glomerular crescent forma-
tion (40). One study proposed heparin as prevention for 
HSP-related kidney disease (47). The use of anticoagu-
lants is generally not well documented and may cause 
serious side-effects. As such, their use is not justified. 
Plasmapheresis has been proposed to remove circulating 
IgA1 and IgA1-complexes, which are responsible for 
organ manifestations. Several case reports relate the dra-
matic improvement of extra-renal symptoms after plasma 
exchange (40). However, the general consensus about 
plasmapheresis is, that it seems effective as an adjuvant 
therapy in a multi-faceted treatment regimen, but larger 
randomized controlled trials are needed to conclude this 
(56). Tonsillectomy has been proposed as a treatment and 
prophylaxis based on several case reports, as HSP is often 
triggered by an upper respiratory tract infection (57). 
However, a suggested link between chronic tonsillitis 
and HSP has not yet been proven.
HENOCH-SCHÖNLEIN PURPURA AND CANCER
Vasculitis is associated with cancer with an incidence of 
~2–5%, and the majority of cases are related to haemato-
logical malignancies. The onset of vasculitis may appear 
before, during or after the cancer diagnosis (5, 58). HSP 
is more commonly associated with solid tumours than 
with haematological malignancies. The gastrointestinal 
tract, respiratory organs and urinary tract are the most 
affected organs (29, 58–60). These patients are mostly 
male, approximately 60 years of age, and screening for 
cancer in this subgroup could be indicated in the case 
of unexplained development of HSP, especially if the 
rash spreads to the trunk and upper extremities (58, 60). 
CONCLUSION
The presentation and diagnostic criteria of HSP are well 
described in the literature. In recent years, there has been 
great progress in research, leading to a better, but still 
not complete, understanding of the pathogenesis. The 
majority of cases are preceded by an upper respiratory 
infection, and patients show vascular depositions of IgA 
immune complexes in several organ systems, which 
lead to the disease manifestations. Screening for cancer 
should be considered in adult patients, especially in males 
approximately 60 years of age who have HSP with no 
preceding infection,. Treatment includes symptomatic, 
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ting, agents, e.g. mycophenolate mofetil or cyclosporine 
A in the case of renal involvement. We recommend that 
immunosuppressants and immunomodulators are res-
tricted to chronic, persistent, recurrent or complicated 
cases. Future multicentre studies in children and adults 
should determine whether corticosteroids are indicated, 
and assess other possible steroid-sparing drugs, such as 
rituximab or dapsone in individual organ manifestations. 
From a clinical point of view, an evidence-based treat-
ment algorithm for HSP based on disease manifestations 
is needed.
The authors declare no conflicts of interest.
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